Sci Rep 5 , 10478 (2015)
Absolute Contraindications BPC-157 is not recommended for patients with: Active cancer (any type) theoretical concern regarding angiogenesis promotion Pregnancy or breastfeeding insufficient safety data Known hypersensitivity to any component of the formulation Relative Contraindications (Require Individualized Assessment) History of cancer after completion of treatment, a waiting period and oncology clearance may be appropriate Autoimmune disease especially if active or requiring immunosuppressive therapy Anticoagulant use injection site bleeding risk, though minimal with proper technique Severe renal or hepatic impairment dosing adjustments may be needed Monitoring and Follow-Up Patients on BPC-157 protocols are monitored through: Baseline and follow-up labs including inflammatory markers (CRP, ESR), complete blood count, and metabolic panel Clinical assessments pain scores, range of motion, functional outcomes at 2-week, 4-week, and 8-week intervals Imaging when indicated repeat ultrasound or MRI for musculoskeletal conditions to document structural healing The Patient Journey: What to Expect For patients considering peptide therapy, understanding the timeline of response helps set realistic expectations
GHK-Cu GHK-Cu Studies and Research Data GHK-Cu and Matrix Renewal and Structural Proteins Work in cell and skin models proposes that GHK-Cu may prompt fibroblasts toward increased matrix synthesis signals, including collagen pathways
However, the Oxford researchers admitted the science is solid on glutathione and NACs ability to combat oxidative stress and inflammation associated with active viral infections, including influenza A
A.RashidS.AliM
Glutathione IV therapy isnt right for everyone, especially those receiving chemotherapy, expecting mothers, or nursing mothers
